Biopharmaceutical company Merck (NYSE:MRK) reported on Tuesday the launch of a definitive agreement to the acquire privately held and Peloton Therapeutics Inc.
Through a subsidiary, Merck will acquire all outstanding shares of Peloton in exchange for an upfront payment of USD1.05bn in cash.
Under the terms of the agreement, Peloton's shareholders will be eligible to receive another USD1.15bn contingent upon successful achievement of future regulatory and sales milestones for certain candidates.
Subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, the acquisition is expected to close in the third quarter of 2019.
Peloton is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Its lead candidate is PT2977, a novel oral HIF-2α inhibitor, is in late-stage development for renal cell carcinoma (RCC). HIF-2α was previously thought to be intractable using small molecules.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval